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Reuse of malaria rapid diagnostic 
tests for amplicon deep sequencing 
to estimate Plasmodium falciparum 
transmission intensity in western 
Uganda
Ross M. Boyce  1, Nick Hathaway2, Travis Fulton3, Raquel Reyes4, Michael Matte5, 
Moses Ntaro5, Edgar Mulogo5, Andreea Waltmann1, Jeffrey A. Bailey2, Mark J. Siedner6 & 
Jonathan J. Juliano1,3,7
Molecular techniques are not routinely employed for malaria surveillance, while cross-sectional, 
community-based parasite surveys require significant resources. Here, we describe a novel use of 
malaria rapid diagnostic tests (RDTs) collected at a single facility as source material for sequencing 
to esimtate malaria transmission intensity across a relatively large catchment area. We extracted 
Plasmodium falciparum DNA from RDTs, then amplified and sequenced a region of the apical membrane 
antigen 1 (pfama1) using targeted amplicon deep sequencing. We determined the multiplicity of 
infection (MOI) for each sample and examined associations with demographic, clinical, and spatial 
factors. We successfully genotyped 223 of 287 (77.7%) of the samples. We demonstrated an inverse 
relationship between the MOI and elevation with individuals presenting from the highest elevation 
villages harboring infections approximately half as complex as those from the lowest (MOI 1.85 vs. 3.51, 
AOR 0.25, 95% CI 0.09–0.65, p = 0.004). This study demonstrates the feasibility and validity of using 
routinely-collected RDTs for molecular surveillance of malaria and has real-world utility, especially as 
the cost of high-throughpout sequencing continues to decline.
To acheieve malaria elimination, there is a need for tools that accurately measure transmission intensity to iden-
tify target areas for public health interventions1–3. The multiplicity of infection (MOI), defined as the number of 
concurrent parasite clones per Plasmodium falciparum-infected host, has shown promise as a surrogate measure 
of malaria transmission intensity4. In the more than twenty years since its first descriptions5–7, the MOI has been 
employed in a variety of roles to include estimating malaria transmission intensity between differing areas8,9, 
assessing changes in transmission intensity over time10,11, and evaluating the impact of interventions ranging 
from chemoprophylaxis12,13 to vaccines14,15.
In malaria endemic areas, the presence of polyclonal infections is common, and caused by infection from mul-
tiple mosquitoes or infection from a single mosquito harboring multiple parasite clones16. The MOI is generally 
considered to be positively associated with the intensity of transmission. As shown in Table 1, significant differ-
ences in the MOI between sites of varying transmission intensity have been consistently demonstrated across 
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sub-Saharan Africa17–31. Host factors such as premunition, however, also impact the MOI5,7,32. Efforts have been 
made to correlate the MOI with age, parasite density, and disease severity, all of which reflect host immunity, with 
mixed results (Table 1).
To estimate MOI, investigators have historically collected dried blood spots (DBS), which allow long-term 
storage of malarial DNA. However, DBS are not collected in routine clinical practice, and require additional 
supplies for sampling and storage, which generally precludes estimation of MOI outside of research studies. 
Moroever, the MOI is traditionally determined using nested PCR (nPCR) with gel electrophoresis to detect 
polymorphisms in the highly variable surface antigens of the merozoite surface proteins (msp-1 & -2) or the 
glutamate-rich protein (glurp)33. However, these techniques are labor intensive and often fail to detect all sequence 
polymorphisms and low-abundance variants34,35. Newer methods utilizing targeted amplicon deep sequencing 
of malaria infections provide a high-throughput, highly sensitive approach for detecting clones in polyclonal 
infections as well as more accurate quantitative estimates of clonal frequency36.
In this study, we investigated the use of a targeted amplicon deep sequencing approach to describe the clonal 
diversity of the P. falciparum apical membrane antigen 1 (pfama1) across a geographically diverse area of western 
Uganda. To achieve this, we extracted DNA from malaria rapid diagnostic tests (RDTs) collected during routine 
care at a single rural health facility and stored at room temperature under tropical conditions. Our primary objec-
tive was to identify spatial differences in the MOI as a surrogate marker of malaria transmission intensity over a 
highland area using only a facility-based sample of routinely-collected rapid tests. While RDTs have previously 
been used as a source of malarial DNA for PCR and the sequencing of drug resistance and mitochondrial poly-
morphisms, they have not been employed to estimate transmission intensity37–41. Our relatively efficient sampling 
strategy precludes the need for more resource-intensive, population-based approaches to mapping transmission 
intensity and parasite diversity. Secondary objectives included an investigation of associations between the MOI, 
age, and the clinical spectrum of malaria, as well as an exploration of the spatial micro-epidemiology of parasites 
based on the pfama1 haplotypes.
Materials and Methods
Study setting. Samples were collected from patients presenting with febrile illness to the Bugoye Level III 
Health Center in the Kasese District of western Uganda. The geography of the study area is highly varied. The 
westernmost villages of the sub-county are characterized by deep river valleys and steep hillsides with elevations 
up to 2,000 meters. In contrast, villages located to the east are defined by low-lying, level terrain (Fig. 1). Three 
large rivers (the Mubuku to the north, Sebwe bisecting the sub-county, and the Nambiaji to the south) flow down 
valleys from west to east converging in the low-lying basin area near the health center. Like much of Uganda, the 
climate in Bugoye permits year-round malaria transmission marked by semi-annual transmission peaks typically 
following the end of the rainy seasons42. The two most recent malaria indicator surveys undertaken in the region 
found declining parasitemia prevalence from 48.4% to 17.6% in 2009 and 2014, respectively43,44.
Sample Selection. Rapid diagnostic tests were performed as part of the Rapid Diagnostic Tests for Severe 
Malaria (RDTSM) study, a prospective, observational cohort study of patients with a parasitological diagnosis 
of malaria conducted from May to November 2015. We have reported full details of the study methodology 
elsewhere45.
Study Country Population Markers Transmission Age Parasitemia Severity
A-Elbasit et al. (2007) Sudan Symptomatic msp-2 — No No No
Amodu et al. (2008) Nigeria Symptomatic msp-2 — — — Yes*
Apinjoh et al. (2015) Cameroon Symptomatic msp-1 — No No —
Bendixen et al. (2001) Tanzania Asymptomatic msp-1/msp-2 Yes Yes Yes —
Durand et al. (2008) Madagascar Symptomatic msp-2 Yes No — No
Engelbrecht et al. (2000) Nigeria Asymptomatic msp-2 — Yes — —
Francis et al. (2006) Uganda Symptomatic msp-2 Yes — — —
Kateera et al. (2016) Rwanda Symptomatic msp-2 Yes Yes Yes —
Kiwuwa et al. (2013) Uganda Symptomatic msp-1/msp-2/csp/glurp — No — Yes**
Mahdi et al. (2016) Sudan Symptomatic msp-1/msp-2 — No — No
Manjurano et al. (2011) Tanzania Asymptomatic msp-2 Yes No — —
Mayor et al. (2007) Mozambique Asymptomatic msp-2 — Yes Yes —
Mockenhaupt et al. (2003) Ghana Asymptomatic msp-2 — No No Yes#
Peyerl-Hoffmann et al. (2001) Uganda Asymptomatic msp-1/msp-2 No Yes Yes —
Shigidi et al. (2004) Sudan Mixed msp-2 — — — Yes##
Table 1. Representative selection of previous studies from sub-Saharan Africa demonstrating the relatively 
consistent association between the multiplicity of infection (MOI) and malaria transmission intensity, 
contrasted with the more variable associations between MOI and patient age, parasite density, and malaria 
severity. *Lower MOI associated with severe malaria. **Higher MOI associated with severe malaria. #Higher MOI 
associated with severe malaria anemia. ##Higher MOI associated with cerebral malaria.
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In brief, initial testing for malaria was performed using the Standard Diagnostics 05FK60 Malaria Ag P.f/Pan 
RDT assay (Standard Diagnostics, Hagal-Dong, Korea). Study RDT were obtained directly from the manufac-
turer, stored in the original packaging at room temperature, and utilized in accordance with the manufacturer’s 
instructions prior to the expiry date. Each day, study staff packaged completed RDTs in a polyethylene bag with 
desiccant. RDTs were stored at room temperature for approximately two years prior to extraction. Study staff with 
training in laboratory medicine prepared thin and thick blood smears for all patients with a positive RDT result. 
Hemoglobin levels were measured using the Hemocue Hb 201+ analyzer (Brea, CA), and venous lactate values 
were obtained using the Abbott iStat analyzer (Princeton, NJ).
We first stratified the RDT-positive results by village. From each village-based strata, we sorted by level of 
parasitemia as determined by microscopy and systematically sampled starting from the highest density sample to 
achieve a balance of high and low parasitemias within each village-based strata. A convenience sample of approx-
imately sixteen RDTs from each village was selected. Post hoc, we found that this number was more than sufficient 
to power the primary analysis at a level of 0.80 (α = 0.05) to detect the observed mean difference in MOI between 
the highest and lowest quartiles of elevation, even accounting for failed genotyping in nearly a quarter of samples.
Laboratory and Bioinformatic Methods. We removed a 1 cm section of the internal filter paper from 
the RDTs according to a previously described protocol (Supplementary Fig. S1)40. DNA was extracted using a 
previously described Chelex extraction method in a final volume of 100 μL46. The concentration of extracted P. fal-
ciparum DNA in individual samples was determined using a quantitative real-time PCR (qPCR) for P. falciparum 
lactate dehydrogenase (pfldh)47. Pfama1 was amplified from individual samples in duplicate in a hemi-nested 
PCR modified from Miller et al., which was shown to reproducibly and accurately determine the frequency and 
haplotype of variants in known mixtures in our laboratory using Ion Torrent sequencing48. In this approach, the 
inner forward primers are labeled with a unique barcode (Supplementary Table S1), referred to as an MID, which 
allows for multiple PCR products to be pooled prior to sequencing library preparation (Supplemental Fig. S2)48. 
We employed 22 unique MIDs, allowing 11 samples to be sequenced in duplicate in each Illumina library. Each 
PCR within a final sequencing library contained a unique MID, thus allowing the PCR replicate for each clinical 
sample to be de-convoluted bioinformatically as described below.
Modifications to the PCR protocol included using 2.5 units of Roche FastStart high fidelity Taq polymerase, 
and final concentrations of 1.8 mM for MgCl2, 200 uM for each dNTP (dATP, dCTP, dGTP, dTTP), and 167 nM 
for forward and reverse primers for each step of the hemi-nested PCR. Thus, all samples were amplified and 
uniquely barcoded in duplicate. Successful amplification was confirmed by visualizing the qPCR products on 
Figure 1. Map of the study area shaded by elevation quartiles. Map created using ArcGIS, Version 10.4.1 (ESRI, 
Redlands, CA) available at http://desktop.arcgis.com/en/.
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a 1% agarose gel and the product was quantified using Quantifluor dsDNA System (Promega, Fitchburg, WI) 
on a Synergy HT Multi-Mode Microplate Reader (BioTek, Winooski, VT). Barcoded samples were then pooled 
in equal amounts based on concentration. Pools of MID labeled PCR products were cleaned using KAPA Pure 
Beads (Illumina, San Diego, CA) and multiple indexed libraries were prepared for sequencing using KAPA Hyper 
Library Prep kits (Illumina, San Diego, CA) using NEXTflex DNA barcodes (BiooScientific, Austin, TX). The 
indexed pools were then combined in equimolar concentration into a final pool that was sequenced on a part of a 
MiSeq (2 × 300 bp chemistry) at the University of North Carolina High Throughput Sequencing Facility. Unlike 
Ion Torrent, Illumina sequencers have problems handling samples with low heterogeneity. We typically use two 
approaches to increase thje heterogeneity on the sequencing runs. First, we include 10% PhiX spike in all of our 
amplicon deep sequencing runs. Second, we often run libraries for other projects on the same run as the amount 
of sequencing necessary for a small project is not sufficient to warrant a complete run. This library comprised an 
estimated 80% of the run which also contained amplicons from other studies.
For these experiements, we included a positive control comprised of a known mixture of three malaria strains: 
3D7 (MRA-102G, BEI Resources, Manansas, VA), FCR3 (MRA-321G, BEI Resources), and Dd2 (MRA-150G, 
BEI Resources). Using this control mixture, pfama1 amplicons were generated for 5 controls, representing 10 
MID labeled PCR reactions, and sequenced alongside the clinical samples. To ensure that we correctly estimated 
the frequency of the three strains in the mixture, we amplified the mixture using the same conditions using only 
the second round reaction for 30 cycles. We cloned the PCR product using a TOPO TA cloning kit (Invitrogen) 
and performed Sanger sequencing of 22 colonies using the M13F primer at GENWIZ (RTP, NC). Sequences were 
analyzed using Geneious R10 (Biomatters Inc., Newark, NJ). We estimated allele frequencies and confidence 
intervals by the bootsrap method with 1,000 replicate bootstraps. This was compared to the allele frequency 
determined by the four replicate control deep sequencing reactions.
The deep sequencing reads were de-multiplexed and clustered using the software package, SeekDeep (http://
baileylab.umassmed.edu/SeekDeep), as previously described49. This approach uses the PCR replicates for each 
sample to reduce PCR and sequencing errors as shown in the SeekDeep Process Cluster step of Fig. 1 of Hathaway 
et al., and has been shown to provide accurate frequency and genotype determinations with as few as 200 reads 
per sample49. As haplotypes in each PCR are called independently and then only haplotypes conserved between 
replicate PCRs are used, this provides a conservative approach for haplotype detection to determine MOI. Here, 
samples were included in the final analysis if they had ≥250 total reads combined between the replicates. The low 
read coverage in some samples did not influence the MOI estimates as seen in Supplemental Fig. S5. Haplotypes 
were included in the analysis if ≥80% of haplotype reads had a Phred Quality Score of ≥30 and if they occurred 
in both sequencing replicates and were above an averaged frequency cutoff of 2.5% between the two PCRs, similar 
to our previous work (i.e. if the within-sample average frequency across duplicate runs was above this cutoff)48. 
Haplotypes that were marked as likely chimeric were excluded. Haplotypes in each sample were compared to all 
identified haplotypes in order to provide population-level statistics. All data generated or analyzed during this 
study are included in this published article and the Sequence Read Archive available at www.ncbi.nlm.nih.gov/
sra (SRA Accession Number Pending).
Statistical analysis. We first summarized demographic, clinical, and laboratory characteristics of the cohort 
using Student’s t-test for continuous variables and Pearson’s Chi squared test for categorical variables. We defined 
severe malaria in accordance with the WHO guidelines for research and epidemiological studies using a threshold 
of ≥250,000 parasites/μl to define hyperparasitemia50.
The MOI was calculated as the number of concurrent parasite clones per P. falciparum-positive sample. We 
performed ordinal logistic regression to explore the demographic, spatial, clinical and laboratory parameters 
associated with the MOI, the primary outcome measure of interest. Age categories were set to be comparable with 
prior studies that found significant associations between age and MOI22,30. All variables that were significant in 
univariate models with a pre-specified P-value of <0.25 were included in the subsequent multivariate analysis51. 
We compared the results of the regression analysis to the RDT positivity rate, defined as the number of positive 
malaria tests per 100 suspected cases examined.
To assess the potential relationship between the MOI and disease severity, we selected three outcomes of 
interest: (a) lactic acid levels, (b) hemoglobin levels, and (c) severe malaria. For the continuous outcomes of 
lactic acid and hemoglobin levels, we first performed linear regression with MOI serving as the primary explan-
atory variable. We then utilized negative binomial general linear regression model with a log-link function and 
robust standard errors to explore associations between the categorical outcomes of (a) lactic acidosis (venous 
lactate ≥5 mmol/L), (b) anemia (hemoglobin <7 g/dL), and (c) severe malaria. Data were analyzed with Stata 
12.1 (College Station, TX).
To estimate associations between geographic factors and the MOI, we completed village-level geographic 
information system (GIS) mapping of the sub-county and surrounding environs, comprising an area of approxi-
mately 55 square kilometers. These data were entered into ArcGIS, Version 10.4.1 (ESRI, Redlands, CA) to create 
a reference map, from which we calculated the mean elevation and area of each village and subsequently divided 
the data into quartiles of elevation.
Ethics statement. Ethical approval of the study was provided by the institutional review boards of the 
University of North Carolina at Chapel Hill, the Mbarara University of Science and Technology, and the Uganda 
National Council for Science and Technology. Written informed consent was obtained from all adult study par-
ticipants and the caregivers of participating children. All research was performed in accordance with relevant 
guidelines and regulations.
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Results
Validation of control mixtures. Allele frequency calls for all five control mixtures are shown in 
Supplemental Fig. S3. Using a previously described measure of concordance for allele frequency calls between 
PCR replicates (do), the replicate PCRs showed a high level of agreement of allele frequencies in each of the five 
controls with a mean do of 0.0252. Using data from the cloned Sanger sequences as the reference standard, we 
evaluated the accuracy of the deep sequencing frequency estimates. We bootstrapped the frequency estimates 
to generate confidence intervals for the Sanger sequence data and compared it to the variation in replicate deep 
sequencing reactions (Supplementary Fig. S4). The amplicon deep sequencing method provided accurate esti-
mates of haplotype frequency, suggesting that haplotype frequencies in the clinical samples were representative. 
No false haplotypes were detected in the control mixtures.
Extraction of genomic DNA from RDTs and amplification of samples. We detected pfldh malarial 
DNA and were subsequently able to amplify pfama1 in 287 of 299 (96.0%) of RDT positive samples. Of the twelve 
RDTs from which we were unable to detect pfldh or pfama1, four were negative on microscopy while another 
four had parasite densities of <250 parasites/μl. We successfully sequenced 223 of the 287 (77.7%) samples with 
detectable malarial DNA. Demographic and clinical characteristics of the cohort are summarized in Table 2. 
There were no significant differences in age (p = 0.28), sex (p = 0.85), parasitemia (p = 0.29), or disease severity 
(p = 0.70) between those samples successfully genotyped and those that were excluded from the analysis.
Multiplicity of Infection. After filtering in SeekDeep, we used 5.56 million of 8.15 million sequencing 
reads to call AMA haplotypes and determine multiplicity of infection in each sample. The mean number of reads 
used per sample was 22,763 (range 254–120,213). Read depth for each sample stratified by MOI is shown in 
Supplementary Fig. S5. The mean and median MOI was 3.09 (95% CI 2.74–3.44) and 2.0 (IQR 1.0–4.0), respec-
tively. The crude monthly mean MOI peaked in May (MOI = 4.68, 95% CI 3.22–6.14), which is the last month of 
the traditional rainy season, and then declined significantly, reaching a nadir in October, (MOI = 2.06, 95% CI 
1.06–3.07, p = 0.003 compared to May), which marks the beginning of the second rainy season.
The MOI varied significantly with geographic factors, including village elevation and river valley of residence. 
The MOI demonstrated an inverse relationship with elevation (Table 3). On average, individuals presenting from 
the highest elevation villages harbored infections approximately half as complex as those from the lowest ele-
vation villages (MOI 1.85 vs 3.51, OR 0.24, 95% CI 0.10–0.57, p = 0.001) (Fig. 2). This finding was robust in the 
final model, which was adjusted for age and disease severity. We also observed a significantly lower MOI among 
individuals presenting from the Sebwe (MOI 2.28, aOR 0.55, 95% CI 0.31–0.97, p = 0.04) and Nambiaji (MOI 
1.75, aOR 0.31, 95% CI 0.11–0.85, p = 0.02) river valleys compared to the basin area (MOI 3.25) where the rivers 
converge. These results were generally consistent with the RDT positivity rates observed in each valley with both 
the Sebwe (aOR 0.84, 95% CI 0.72 – 0.0.97, p = 0.02) and Nambiaji (aOR 0.64, 95% CI 0.50–0.81, p < 0.001) river 
valleys being significantly lower than the basin area.
The highest MOI was found in children age 3 to 4 years of age (MOI = 3.47, 95% CI 1.99–4.96) compared to 
those aged 8–11 years of age, who had the lowest MOI (2.97, 95% CI 2.21–3.74). Differences by age, however, were 
not significant as shown in Table 3 or when age groups were broadened to include children <5 years of age, 5 to 15 
years of age, and ≥15 years of age (Supplementary Table S2). No clinical factors were associated with the degree of 
infection complexity. While there were trends towards lower MOI with severe disease in the univariate regression 
analysis, these findings were not significant in adjusted models.
When we defined severe malaria as the outcome measure of interest, we found strong correlations with male 
sex, age less than five years, and parasite density greater than 100,000 parasites/μl in the 21 cases of severe disease 
(Table 4). There was, however, no significant difference in the proportion of patients with polyclonal infections 
Total Gentoyped Excluded p-value
Patients (n, %) 287 (100) 223 (77.7) 64 (22.3) —
Age (median, IQR) 12 (7–20) 12 (7–20) 12 (6–22.5) 0.28
Female 144 (50.5) 111 (50.2) 33 (51.6) 0.85
Febrile 71 (25.8) 60 (28.3) 11 (17.5) 0.08
Microscopy
P. falciparum 267 (95.7) 211 (97.7) 56 (88.9)
0.008Mixed Infection 6 (2.2) 3 (1.4) 3 (4.8)
Negative 6 (2.2) 2 (0.9) 4 (6.4)
Parasite Density (GM, IQR) 9,701/μl (3,318–28,001) 10,400/μl (3,623–26,488) 8,531/μl (2,058–39,838) 0.29
<2,500/μl 61 (21.3) 45 (20.2) 16 (25.0)
0.59
2,500–9,999/μl 78 (27.2) 60 (26.9) 18 (28.1)
10,000–99,999/μl 105 (36.6) 86 (38.6) 19 (29.7)
≥100,000/μl 43 (15.0) 32 (14.4) 11 (17.2)
Lactate (mean, 95% CI) 2.02 (1.89–2.15) 2.00 (1.87–2.14) 2.07 (1.72–2.43) 0.66
Hemoglobin (mean, 95% CI) 12.2 (11.9–12.5) 12.2 (11.9–12.5) 12.3 (11.8–12.9) 0.78
Severe Malaria 28 (10.7) 21 (10.3) 7 (12.1) 0.70
Table 2. Baseline demographic, laboratory, and clinical characteristics of cohort.
www.nature.com/scientificreports/
6Scientific REPORTS |  (2018) 8:10159  | DOI:10.1038/s41598-018-28534-3
among patients with uncomplicated versus severe malaria (66.1 vs. 57.1%, p = 0.41). Increasingly complex infec-
tions (≥3 identified haplotypes) demonstrated a trend towards a reduced risk of severe malaria although this 
finding was not significant in the multivariate model (aIRR 0.65, 95% CI 0.25–1.73, p = 0.39), which was adjusted 
for age. Of note, when the analysis was stratified by age, we found that risk of severe malaria was non-significantly 
higher with more complex infections (IRR = 1.67, 95% CI 0.34–8.06, p = 0.53) in children <5 years of age, while 
the risk of severe malaria trended lower with more complex infections in children and adults ≥5 years of age (IRR 
0.24, 95% CI 0.05–1.12, p = 0.07).
Similarly, there was no association between the MOI and disease severity when we defined lactic acidosis 
(>5 mmol/L) or anemia (Hb < 7 g/dL) as the outcome measure of interest. While lactic acidosis and anemia were 
relatively rare outcomes in the cohort, we did not observe any trend between lactic acid (β coefficient = 0.02, 95% 
CI −0.03–0.07, p = 0.40) or hemoglobin levels (β coefficient = 0.07, 95% CI −0.04–0.17 p = 0.20) and the MOI in 
the linear regression models.
Haplotype Analysis. A total of 39 unique haplotypes were identified [SRA Accession Number Pending]. 
The most common haplotype (UgandaMOI.00) was found in 122 of 223 (54.7%) of the included samples and 
accounted for 24.6% of the population fraction. The distribution of haplotypes in the population are shown in 
Supplementary Fig. S6. Approximately two thirds of included samples (n = 139, 62.3%) demonstrated polyclonal 
infections with the highest proportion observed in individuals 18 to 30 years of age (n = 28, 68.3%). In contrast, 
monoclonal infections were most common in children <3 years of age (n = 11, 57.9%).
In the clustering analysis, we did not identify any evidence of population structure based on either haplotype 
prevalence (the proportion of infections containing the respective haplotype), or haplotype relative abundance 
(the proportion of the respective haplotype within an individual infection), when plotting by elevation, river 
valley or the presence/absence of severe malaria. (Fig. 3).
Discussion
We carried out targeted amplicon deep sequencing from DNA extracted from routinely-collected RDTs among a 
facility-based cohort of symptomatic individuals and were able to demonstrate a significant, inverse correlation 
between village elevation and the MOI, consistent with previous observations27. We also found a lower MOI in two 
of the river valleys, which correlated with the RDT positivity rate, a crude measure of transmission intensity. Our 
findings are proof-of-concept that it is possible to estimate transmission intensity across a wide catchment area 
using only a facility-based sample of routinely-collected RDTs, thus negating the need for additional DBS collec-
tion or labor-intensive cross-sectional sampling. Such an approach has relatively broad programmatic application 
and may even be cost-effective when considering the labor costs associated with large cross-sectional surveys.
Variable Mean MOI OR (95% CI) p-Value aOR (95% CI) p-Value
Sex
Female 3.16 (2.65–3.67) REF REF — —
Male 3.00 (2.51–3.49) 0.89 (0.56–1.44) 0.64 — —
Age Category
<3 years 2.16 (1.09–3.23) REF REF REF REF
3–4 years 3.47 (1.99–4.96) 2.82 (0.81–9.86) 0.10 1.11 (0.19–6.60) 0.91
5–7 years 3.00 (1.80–4.20) 2.37 (0.72–7.82) 0.16 1.57 (0.26–9.41) 0.63
8–11 years 2.97 (2.21–3.74) 2.50 (0.92–6.84) 0.07 1.45 (0.33–6.39) 0.62
12–17 years 3.05 (2.44–3.66) 2.51 (0.97–6.52) 0.06 1.35 (0.32–5.66) 0.68
18–29 years 3.46 (2.60–4.33) 3.17 (1.14–8.78) 0.03 1.53 (0.36–6.52) 0.57
≥30 years 3.26 (1.98–4.54) 2.39 (0.74–7.75) 0.15 0.85 (0.16–4.) 0.84
Parasitemia
<2,500/μl 3.51 (2.55–4.47) REF REF — —
2,500–9,999/μl 3.52 (2.75–4.29) 1.22 (0.53–2.84) 0.64 — —
10,000–99,000/μl 2.80 (2.34–3.27) 0.96 (0.45–2.06) 0.91 — —
≥100,000/μl 2.47 (1.79–3.15) 0.77 (0.32–1.85) 0.56 — —
Severity
Uncomplicated 3.25 (2.86–3.64) REF REF REF REF
Severe 2.29 (1.46–3.12) 0.56 (0.27–1.16) 0.12 0.60 (0.23–1.52) 0.28
Elevation*
Quartile 1 3.51 (2.77–4.26) REF REF REF REF
Quartile 2 2.70 (2.08–3.33) 0.51 (0.23–1.12) 0.09 0.42 (0.17–1.02) 0.06
Quartile 3 2.62 (2.06–3.19) 0.49 (0.22–1.08) 0.08 0.45 (0.20–1.04) 0.06
Quartile 4 1.85 (1.33–2.37) 0.24 (0.10–0.57) 0.001 0.25 (0.09–0.65) 0.004
Table 3. Mean multiplicity of infection (MOI) by sub-group and ordinal logistic regression modeling of 
correlates of MOI. Elevation ranges: Quartile 1 = 1136–1225 m, Quartile 2 = 1259–1339 m, Quartile 3 = 1355–
1424 m, Quartile 4 = 1451–1830 m Abbreviations: OR = odds ratio, aOR = adjusted odds ratio.
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In contrast, we found no evidence of population structure by elevation or river valley based on the pfama1 
haplotypes. This outcome is not entirely unexpected, as it likely reflects the high intensity of transmission and 
resulting mixing of parasite sub-populations across the study site. It is also supported by our recent work showing 
no population structure based on this gene between distant geographic sites in Africa48. We had hypothesized that 
the high ridgelines separating the three major rivers could serve as a physical barrier to vector migration, isolating 
each valley from the next. Our results, however, could suggest that this barrier is inadequate to maintain popu-
lation structure, most likely at the lower elevation areas where the rivers merge into the basin area. In addition, 
human movement into lower elevation areas, where most commercial activity occurs, could also facilitate the 
mixing of parasite populations between river valleys. Alternatively, the lack of structure could also result from the 
choice of marker. Antigens like pfama1 may be under convergent evolution and thus similar patterns of diversity 
emerge in distant populations, as supported by our previous work53,54.
We did not identify any associations between the MOI and age or the MOI and markers of disease severity 
(i.e. anemia, lactate, severe malaria). However, given the few cases of severe malaria (n = 21), our analysis was 
only powered to a level of 0.54 to detect a mean difference of one parasite clone between cases of uncomplicated 
Figure 2. Multiplicity of infection (MOI) stratified by elevation quartiles showing that mono-infections 
comprised the smallest proportion of infections in the lowest elevation villages (Quartile 1) and the highest 
proportion in the highest villages (Quartile 4).
Variable
Risk Ratio 
(IRR) 95% CI p-Value
Adjusted 
RR 95% CI p-Value
Sex
Male 1.86 0.89–3.87 0.10 3.05 1.40–6.64 0.005
Age Category
≥15 years REF REF REF REF REF REF
5 to 14 years 2.62 0.99–6.93 0.05 5.90 0.77–45.2 0.09
<5 years 4.70 1.60–13.8 0.005 8.39 1.06–66.6 0.04
Parasitemia
<2,500/μl REF REF REF REF REF REF
2,500–10,000/μl 0.76 0.11–5.25 0.78 0.42 0.04–4.76 0.48
10,000–100,000/μl 3.49 0.81–15.1 0.09 1.12 0.28–4.46 0.88
≥100,000/μl 10.7 2.54–44.9 0.001 5.38 1.39–20.8 0.02
Fever
Febrile 2.24 1.09–4.56 0.03 1.14 0.53–2.49 0.73
MOI Category
MOI=1 REF REF REF REF REF REF
MOI=2 1.06 0.42–2.67 0.91 1.47 0.57–3.78 0.42
MOI≥3 0.49 0.17–1.39 0.18 0.65 0.25–1.73 0.39
Table 4. Negative binomial regression modeling of correlates of severe malaria (n = 21).
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and severe malaria. Interestingly, we did observe a divergent effect of infection complexity on the risk of severe 
malaria among children <5 years of age, who had a relatively negligible risk of severe disease with a more com-
plex infection (≥3 identified haplotypes), compared to adults and children ≥5 years of age, who had a clear 
trend (p = 0.07) towards a reduced risk of severe disease with more complex infections. This finding supports 
the hypothesis of age-dependent immune response mechanisms and is consistent with a report from Tanzania 
in which children <3 years of age experienced a greater risk of a subsequent malarial episode with increasing 
infection complexity, whereas in older children, more complex infections were associated with a decreased risk 
of clinical malaria,55.
Our study has several limitations. First, we did not utilize traditional measures of transmission intensity such 
as the entomological inoculation rate (EIR) or parasite prevalence against which we could compare our results. 
However, the relationship between elevation and transmission intensity is well established56 and thus we are con-
fident that our findings in regard to the association between the MOI and elevation are valid. Second, we did 
not perform genotyping from samples stored on DBS, which would have allowed direct comparison between the 
two methods of sample collection, although previous studies have reported similar PCR success rates with each 
approach38,40. Lastly, we were unable to genotype 64 (22.3%) of our samples. This is likely a result of our conserv-
ative duplicate reading thresholds. We are reassured that there were no significant differences in demographic, 
clinical, or laboratory parameters between those samples that were successfully genotyped and those that were not.
Conclusions
Using routinely-collected malaria RDTs from a single health facility as source material, we were able to deep 
sequence and estimate malaria transmission intensity across a large and geographically diverse catchment area. 
To our knowledge, this is the first study to demonstrate the feasibility and validity of such an approach, which we 
believe has practical implications for malaria surveillance programs, especially as the cost of high-throughput 
sequencing continues to decline. Similar techniques may also be applicable to other disease conditions where 
lateral flow assays are commonly utilized for point-of-care diagnosis.
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